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Glioblastoma multiforme (GBM) is an aggressive brain tumor driven by cells with hallmarks of neural stem (NS)
cells. GBM stem cells frequently express high levels of the transcription factors FOXG1 and SOX2. Here we show
that increased expression of these factors restricts astrocyte differentiation and can trigger dedifferentiation to a
proliferative NS cell state. Transcriptional targets include cell cycle and epigenetic regulators (e.g., Foxo3, Plk1,
Mycn, Dnmt1, Dnmt3b, and Tet3). Foxo3 is a critical repressed downstream effector that is controlled via a con-
served FOXG1/SOX2-bound cis-regulatory element. Foxo3 loss, combined with exposure to the DNA methylation
inhibitor 5-azacytidine, enforces astrocyte dedifferentiation. DNA methylation profiling in differentiating astro-
cytes identifies changes at multiple polycomb targets, including the promoter of Foxo3. In patient-derived GBM
stemcells, CRISPR/Cas9 deletion of FOXG1 does not impact proliferation in vitro; however, upon transplantation in
vivo, FOXG1-null cells display increased astrocyte differentiation and up-regulate FOXO3. In contrast, SOX2
ablation attenuates proliferation, and mutant cells cannot be expanded in vitro. Thus, FOXG1 and SOX2 operate
in complementary but distinct roles to fuel unconstrained self-renewal inGBMstemcells via transcriptional control
of core cell cycle and epigenetic regulators.
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Glioblastoma multiforme (GBM) is a highly aggressive
brain tumor driven by neural stem (NS) cell-like cells. It
is increasingly clear that the transcriptional and epigenet-
ic mechanisms that control the initiation and mainte-
nance of NS and progenitor cells are hijacked and
deregulated in GBMs (Singh et al. 2003; Patel et al. 2014;
Suvà et al. 2014). Neurodevelopmental transcription fac-
tors (TFs; e.g., basic helix–loop–helix [bHLH], SOX, FOX,
and HOX families) are known to be critical regulators of
NS cell self-renewal and differentiation. However, TFs
are difficult to “drug”with smallmolecules. Improved un-
derstanding of the role of thesemaster regulators and their
key downstream effectors is needed.
We reported previously that FOXG1 is one of the most
consistently overexpressed genes when comparing prima-
ry cultures of GBM-derived NS (GNS) cells and genetical-
ly normal NS cells (Engström et al. 2012). FoxG1 is a
member of the forkhead box family of TFs. During devel-
opment, it has an essential role in regulating forebrain ra-
dial glia/neural progenitor cell proliferation and limiting
premature differentiation (Xuan et al. 1995; Martynoga
et al. 2005; Mencarelli et al. 2010).
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Although FOXG1 is not genetically amplified in glio-
ma, FOXG1mRNA levels in primary tumors are inverse-
ly correlated with patient survival (Verginelli et al. 2013).
Recently, Liu et al. (2015) demonstrated that the onco-
genic EGFR truncation (EGFRvIII)—found in a significant
proportion of “classical” subtype GBMs—operates in
part by triggering expression of FOXG1. FOXG1 protein
has been shown previously to operate by attenuating
the cytostatic effects of TGF-β signaling by binding and
sequestration of FOXO/SMAD complexes in established
glioblastoma cell lines (Seoane et al. 2004). These find-
ings suggest that increased levels of FOXG1 in GBM
might be functionally important in driving tumor
growth. Evidence in favor of this hypothesis has been pro-
vided by shRNA knockdown of FOXG1 in GBM stem
cells, which leads to reduced proliferation of the resulting
tumors (Verginelli et al. 2013). Despite these observa-
tions, we have a poor understanding of the functional
consequences of its increased levels and the downstream
transcriptional targets in both NS cells and GBM stem
cells.
SOX2 is an established stem cell “master” regulator
highly expressed in multiple tissue stem cells, including
various types of NS and progenitor cells (Arnold et al.
2011). It has important functions within the pluripotent
epiblast, embryonic stem cell cultures, neuroepithelial
progenitors, and multipotent radial glia (fetal, postnatal,
and adult) (Avilion et al. 2003). In Xenopus, chicken,
and mouse embryos, the constitutive expression of Sox2
respecifies gastrulation stage progenitor cells into neuro-
ectoderm at the expense of other lineages (Kishi et al.
2000; Zhao et al. 2004). It is genetically amplified in
∼4% of GBM samples (Brennan et al. 2013). Knockdown
experiments have indicated that SOX2 is required to
sustain the aggressive growth and infiltrative behavior of
GBMs (Gangemi et al. 2009; Alonso et al. 2011).
Together, these studies point to an important role for
FOXG1 and SOX2 in NS cells and their potential deregu-
lation in GBM. FoxG1 and Sox2 are also established repro-
gramming factors: Forced coexpression can trigger direct
reprogramming of fibroblasts to an NS cell-like state
(Lujan et al. 2012). The excessive levels or activity of these
factors in GBM may therefore operate intrinsically to re-
strict tumor cell differentiation through perpetual repro-
gramming to a radial glia-like NS cell state. Despite the
frequent expression of FOXG1/SOX2 in GBM, we have
only a poor understanding of their downstream transcrip-
tional targets and how they operate to drive proliferation
and limit terminal differentiation.
Here we define genome-wide transcriptional targets of
both factors and show that FOXG1/SOX2 can act at
shared target loci encoding core cell cycle and epigenetic
regulators. Loss-of-function studies suggest that they
have context-specific functions, with SOX2 essential for
proliferation, while FOXG1 protects cells from differenti-
ation cues both in vitro and in vivo. These two transcrip-
tional regulators therefore cooperate in functionally
distinct but complementary roles to limit astrocyte differ-
entiation commitment in GBM and enforce the prolifera-
tive NS cell-like phenotype.
Results
HumanGBM stem cells express elevated levels of FOXG1
and exhibit an open chromatin profile enriched for FOX/
SOX motifs
To explore the role of FOXG1, we first extended our previ-
ous finding of elevated FOXG1mRNAexpression inGBM
by assessing the levels of FOXG1 protein. FOXG1 protein
is consistently and highly expressed across a set of nine in-
dependent patient-derived GNS cell lines when compared
with NS cells (Fig. 1A). It is also increased in a mouse
glioma-initiating cell line (Supplemental Fig. S1A).
SOX2 protein levels are high in both NS and GNS cells.
OLIG2, a developmental TF often expressed in GBM, is
more variably expressed between GNS lines (Fig. 1A).
High levels of FOXG1 in GNS cells might contribute to
a modified chromatin landscape compared with karyo-
typically normal NS cells. To assess chromatin accessibil-
ity genome-wide in GNS and NS cells, we performed
ATAC-seq (assay for transposase-accessible chromatin
[ATAC] using sequencing) (Buenrostro et al. 2013). Seven
independent human GNS lines (G7, G19, G25, G26,
G144, G166, and G179) and four human NS cell controls
were assayed in biological duplicates under proliferative
culture conditions. Unsupervised clustering using the
most variable sites across these libraries clearly separated
GNS cells from NS cells (Fig. 1B). As expected, given
patient heterogeneity, GNS cells had a greater diversity
of chromatin profiles than NS cells. Interestingly, the re-
gions identified as more accessible in GNS cells versus
NS cells were enriched in the forkhead box motif and
HMG box motif, which are bound by FOX and SOX fac-
tors, respectively (Fig. 1C). These data suggest that in-
creased FOXG1 protein levels and FOX/SOX-enriched
chromatin accessibility sites are a hallmark that distin-
guishes GNS cells from genetically normal NS cells.
Loss of FOXG1 sensitizes NS cells to astrocyte
differentiation cues
Mouse NS cell cultures are a genetically and experimen-
tally tractable model for interrogating self-renewal and
differentiation commitment. Replacement of the growth
factors EGF/FGF-2 with BMP4 results in prompt and
uniform cell cycle exit and up-regulation of astrocyte
markers, including Gfap and Aqp4 (Fig. 2A–C; Conti
et al. 2005). We used this culture system to explore the
specific and shared functions of Foxg1 and Sox2.
Sox2 has been shown previously to be essential for NS
cell self-renewal in vitro (Gómez-López et al. 2011). To
test whether Foxg1 is required for in vitro self-renewal of
NS cells, we derived a new NS cell line (termed FF) from
the subventricular zone (SVZ) of a previously reported
adult Foxg1flox/flox mouse (Supplemental Fig. S2A;
Miyoshi and Fishell 2012). Transient transfection with a
Cre expression plasmid resulted in biallelic excision of
the Foxg1-coding locus. Monitoring of the Foxg1 ablated
cells over many passages using a GFP reporter of Cre exci-
sion suggested that there was no proliferation deficit
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(Supplemental Fig. S2B). Indeed, we could readily estab-
lish clonal Foxg1 ablated NS cell lines (Fig. 2D). The mu-
tant cells demonstrated no difference in proliferation or
marker expression when grown in EGF/FGF-2; they also
retained astrocyte differentiation potential (Supplemental
Fig. S2B,C). However, in response to a combination of
BMP4 and reduced amounts of EGF/FGF-2, Foxg1−/− cells
showed an increased propensity to exit cycle and differen-
tiate (Fig. 2E). These data suggest that Foxg1 is dispensable
for the maintenance of continued NS cell proliferation in
vitro. It may be required instead to protect cells from dif-
ferentiation commitment.
Overexpression of FOXG1 and SOX2 in adult NS cells
suppresses BMP-induced astrocyte differentiation
The high levels of FOXG1 and SOX2 in GBM stem cells
may underlie the failure of differentiation commitment
and unconstrained self-renewal associated with these ma-
lignancies (Carén et al. 2015). To test the consequences of
increased FOXG1 and SOX2, we transfected genetically
normal adult subependymal zone (SEZ)-derived mouse
NS cell cultures (ANS4)with a stably integrating PiggyBac
transposon plasmid carrying a tetracycline-inducible
FOXG1-2A–SOX2 expression cassette (Fig. 2F). Clonal
NS cell lines were generated that responded to doxycy-
cline (Dox) treatment by increasing expression of
FOXG1 and SOX2 mRNAs in a dose-dependent manner
(Fig. 2F–H). We used the human FOXG1- and SOX2-cod-
ing sequence, as the major goal was to uncover their roles
in humanGBMand these are each∼97% identical to their
mouse orthologs at the protein level, with 100% homolo-
gy in the DNA-binding domains (Supplemental Fig. S2D).
In parallel, we established inducible lines expressing
FOXG1 or SOX2 individually (termed F6 and S15, respec-
tively) (Supplemental Fig. S2E,F). FOXG1 was expressed
as a fusion proteinwith aV5 epitope tag that enabledmon-
itoring of transgene expression.
We cultured FS3, F6, and S15 cells in self-renewal medi-
um (EGF/FGF-2) plus BMP4 with or without Dox. Under
these conditions, parental ANS4 cells adopt an astrocyte
morphology and stop proliferating. Dox-induced expres-
sion of either FOXG1 or SOX2 alone had little effect on
astrocyte differentiation, and cells did not proliferate.
However, coexpression of both factors restricted the dif-
ferentiation response, and cultures remained proliferative
(Fig. 2I,J). These data indicate that overexpression of
FOXG1 and SOX2 in combination can attenuate the cyto-
static effects of BMP-induced astrocyte differentiation.
Overexpression of FOXG1 and SOX2 in post-mitotic
astrocytes triggers dedifferentiation to a proliferative
NS cell-like state
We next explored the functional consequences of forced
expression of FOXG1 and SOX2 in differentiating astro-
cytes. A quantitative in vitro colony-forming assay was
developed to determine whether these factors can trigger
cells to re-enter cell cycle and dedifferentiate to the prolif-
erative NS cell state (Fig. 3A). As a positive control, we
used a previously reported glioma-initiating mouse NS
cell line, IENS (Ink4a/ARF deletion, EGFRvIII overexpres-
sion) (Bachoo et al. 2002; Bruggeman et al. 2007). IENS
cells express FOXG1 at high levels relative to normal
NS cells (ANS4) and are highly malignant on transplanta-
tion (Supplemental Fig. S1B).
When ANS4 cells are plated at low density (10 cells per
square millimeter) and cultured for 24 h in the presence
of BMP4 but without the growth factors EGF/FGF-2, all
cells undergo astrocyte differentiation and are subse-
quently unable to re-enter cell cycle when re-exposed to
self-renewal medium, as assessed by EdU incorporation;
Figure 1. FOXG1 and SOX2 are consistently expressed at high levels across GNS cells. (A) Western blot to determine levels of FOXG1,
SOX2, and OLIG2 expression across a set of GNS cells and normalNS controls. (B) ATAC-seq (assay for transposase-accessible chromatin
[ATAC] using sequencing) libraries were generated inNS andGNS cells. The 100most differentially accessible sites across biological rep-
licates of nine GNS cell lines and four NS cells were identified and are shown in a heat map. (C ) Themost differentially accessible loci are
enriched for key NS-specific TF motifs, most significantly the forkhead box motif.
Elevated FOXG1/SOX2 drives NS cell identity
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Figure 2. FOXG1/SOX2 overexpression can inhibit BMP-induced astrocyte differentiation. (A) Mouse NS cell lines provide an experi-
mentally tractable model to study astrocyte differentiation. BMP4 treatment for 24 h is sufficient to trigger efficient differentiation:
cell cycle exit, adoption of astrocyte morphological features (flattened or star-shaped), and up-regulation of Gfap. (B) Twenty-four hours
after replacing EGF/FGF-2with BMP4,morphological changes are accompanied by down-regulation of Ki67 and up-regulation of Gfap. (C )
Quantitative RT–PCR (qRT–PCR) analysis shows that, at a population level, BMP4 treatment of NS cells at low density (10 cells per
square millimeter) results in significant down-regulation of Nestin and Olig2 and up-regulation of astrocyte markers Gfap, Aqp4, and
S100β. Mean ± SD. n = 3. Significance was assessed by Student’s t-test with Holm-Sidak correction for multiple comparisons. (∗) P≤
0.05; (∗∗) P≤ 0.01; (∗∗∗) P≤ 0.001. (D) Western blot to show that Foxg1 levels in clones picked following Cre treatment of Foxg1fl/fl NS cells
demonstrate an absence of protein expression. (E) Ki67 immunocytochemistry (ICC) was used to score proliferation in Foxg1 ablated cells
(nanograms per milliliter). (F ) A doxycycline (Dox)-inducible transgene cassette was designed to enable inducible coexpression of FOXG1
and SOX2. (TRE) TET-responsive element; (V5) V5 epitope tag; (P2A) porcine teschovirus-1 2A self-cleaving peptide sequence; (PB) piggy-
Bac; (BSD) blasticidin resistance; (IRES) internal ribosome entry site. Western blot (below) confirmed dose-dependent increases in FOXG1
and SOX2 protein levels. (G) ICC for V5 and SOX2 confirms a Dox-induced (1000 ng/mL) increase in V5-FOXG1 and SOX2 levels. (H)
Clonal lines (F6, F11, and FS3) harboring the inducible cassettes (shown in F ) (Supplemental Fig. S2E,F) were generated, and transgene
mRNA levels were determined by qRT–PCR following exposure to growth medium supplemented with different concentrations of
Dox. (I ) Growth curves for mouse NS cells cultured in medium supplemented with 8 ng/mL each mitogens EGF/FGF-2 plus 2 ng/mL
BMP4 either with or without induction of FOXG1/SOX2 overexpression by Dox. Significance was assessed by Student’s t-test: FS3
+Dox versus FS3−Dox, n = 3; P < 0.001 at all time points after 178 h. (J) Phase contrast images of FS3 cells cultured inmediumsupplement-
ed with 8 ng/mL each mitogens EGF/FGF-2 plus 2 ng/mL BMP4 with or without Dox supplementation after 24 h and 10 d.
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Figure 3. FOXG1/SOX2 drives reacquisition of NS cell identity in post-mitotic astrocytes. (A) Schematic of the experimental strategy
used to test dedifferentiation. Cells at clonal density (10 cells per square millimeter) were treated with 10 ng/mL BMP4 for 24 h and
then switched to EGF/FGF-2 mediumwith or without transgene induction by Dox treatment. (B) EdU staining shows that no rapidly cy-
cling cells remain after 24 h of BMP4 treatment. Twenty-four hours after plating in EGF/FGF-2 or BMP4, a 24-h pulse of EdU was admin-
istered in medium containing EGF/FGF-2. Representative images of EdU staining and quantification of the percentage of EdU-positive
cells are shown for each condition. Mean ± SD. n = 2 independent experiments. Bar, 100 µm. (C ) Transgene dose determines the extent
of colony formation after 10 d in EGF/FGF-2. n = 3 independent experiments. Tumor-initiating IENS cells retained colony-forming ability
after BMP treatment and served as a positive control, while ANS4 cells served as a negative control. Below are shown example 10-cm
dishes for FS3 (no Dox), FS3 plus 1000 ng/mL Dox, and IENS treated with BMP4 for 24 h and returned to EGF/FGF-2 for 10 d. FS3 cells
form colonies efficiently on transgene induction. (D) ICC for FS3 cells showing Gfap and Nestin protein levels after 24 h in EGF/FGF-
2, 24 h in BMP4, return to EGF/FGF-2 for 10 d without Dox, and return to EGF/FGF-2 for 10 d with Dox. (E) Heat map of the most differ-
entially expressed transcripts across RNA sequencing (RNA-seq) libraries at various time points during dedifferentiation; biological rep-
licates are shown for each condition, with variability at early stages due to the low absolute numbers of cells that dedifferentiate. (F ) FS3
cells retain astrocytic and neuronal differentiation potential after long-term expansion (∼30 d), as shown by ICC for Gfap and Tuj1. (G)
Mouse primary astrocytes were derived from a postnatal day 3 (P3) mouse cortex, and the FOXG1/SOX2-inducible transgene was intro-
duced by lipofection. Following the described colony-forming assay, colonies were scored 2 wk following restoration of EGF/FGF-2. (H) A
working model: In the presence of mitogens, FOXG1/SOX2 acts to restrict differentiation commitment and drive proliferation.
Elevated FOXG1/SOX2 drives NS cell identity
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i.e., they are post-mitotic and growth factor-unresponsive
(Fig. 3B; Supplemental Fig. S3A).When returned to self-re-
newal conditions, glioma-initiating IENS cells form scat-
tered proliferating NS cell-like colonies, consistent with
a suppression of BMP-induced differentiation (Fig. 3C).
Dox-induced expression of exogenous FOXG1 and
SOX2 in the growth factor-unresponsive and post-mitotic
astrocytes (BMP-treated FS3 cells) resulted in dose-depen-
dent colony formation (Fig. 3C), whereas the “no Dox”-
treated controls failed to form colonies. The colonies
that emerged in Dox-treated plates were rapidly cycling
and comprised Nestin-high, Gfap-low cells with a charac-
teristic NS cell morphology (Fig. 3D). FOXG1/SOX2-
induced colonies were typically similar in size to control
NS cell colonies (data not shown). Inspection of time-
lapse imaging of dedifferentiation revealed doubling times
of ∼24 h, which is comparable with parental NS cells and
suggests that cells rapidly adopt a highly proliferative NS
cell-like phenotype (Supplemental Fig. S3B; Supplemental
Movie 1). Transcriptome profiling of these cells by RNA
sequencing (RNA-seq) identified expression changes com-
patible with dedifferentiation and reacquisition of many
features of the untreated parental cells grown in EGF/
FGF-2 (Fig. 3E), such as differentiation potential (Fig. 3F).
The dedifferentiated cells continued to divide upon Dox
withdrawal and could be serially passaged; they exhibited
morphology, proliferation, and marker expression similar
to the parental FS3 cells (Supplemental Fig. S3C–E). They
also remained BMP4-responsive and activated Gfap (Sup-
plemental Fig. S3F).
To exclude the possibility that FOXG1/SOX2-induced
astrocyte dedifferentiation was limited to in vitro generat-
ed astrocytes, we next introduced the TET–FOXG1-2A–
SOX2 transgene into freshly isolated mouse astrocytes
(Fig. 3G). Induction of FOXG1 and SOX2 in primary astro-
cytes contributed to a significant increase in NS cell-like
colonies when cells were transferred into self-renewalme-
dium. We conclude that overexpression of FOXG1 and
SOX2 in astrocytes reverses differentiation and is suffi-
cient to drive cells to enter cell cycle and acquire a prolif-
erative NS cell identity (Fig. 3H).
ChIP-seq (chromatin immunoprecipitation [ChIP]
combined with high-throughput sequencing) identifies
FOXG1 binding at core cell cycle and methyltransferase
target genes
The in vitro dedifferentiation assay provided a tractable
system to define transcriptional target genes through
which FOXG1 and SOX2 operate. Sox2 target genes in
mouse neural progenitor cells have been defined previous-
ly using ChIP-seq (Lodato et al. 2013). Identification of
FOXG1 targets has been hindered by the limitations of
available native antibodies. To overcome this, we per-
formed ChIP-seq in NS cells constitutively expressing
the V5 epitope-tagged version of FOXG1, which remained
functional in our earlier dedifferentiation assays (Fig. 3).
Two independent NS cell lines constitutively overex-
pressing FOXG1-V5 were generated from either ANS4 or
an independent primary adult SVZ-derived NS cell line.
From the V5 ChIP-seq, we identified 6897 high-confi-
dence binding sites shared between these cell lines, and
motif enrichment analysis confirmed the canonical fork-
head motif to be most significantly enriched (Fig. 4A).
We also found many other neurodevelopmental lineage-
affiliated TF motifs enriched at these sites, including
bHLH, HMG box (the SOX family-binding motif), and
CTF/NF1 factors (Fig. 4A). These are bound by TFs recog-
nized as key components of the core circuit of self-renewal
in NS cells (Mateo et al. 2015). Genes associated with
these peaks were enriched in several notable gene ontolo-
gy (GO) categories, including Notch and TGF-β signaling,
stem cell maintenance, and methyltransferase/histone
methyltransferase function (Supplemental Fig. S4). Mito-
chondrial GO terms were also identified, consistent
with reports of a role for FoxG1 in the regulation of mito-
chondrial function (Pancrazi et al. 2015).
We next examined the intersection of newly defined
FOXG1 peaks with the 16,683 sites previously reported
as bound by Sox2 in cultured mouse neural progeni-
tors (Lodato et al. 2013). There was a substantial
overlap, with 3856 of the 6897 FOXG1 peaks also repre-
sented in the Sox2 data set (Fig. 4B). The associated set
of genes is strongly enriched for GO categories, including
Notch signaling, the histone methyltransferase com-
plex, the mitotic cell cycle checkpoint, and stem cell
maintenance (Fig. 4C). This is consistent with the func-
tional consequences of overexpression of FOXG1/SOX2
(namely, cell cycle re-entry and dedifferentiation) and sug-
gests that both factors may play a role in controlling these
processes.
On its own, binding of a TF does not provide evidence
of a functional role in regulating the candidate target
gene. RNA-seq was therefore performed in order to
identify a subset of candidate FOXG1/SOX2-regulated
loci (Fig. 4D). As anticipated, BMP exposure rapidly led
to down-regulation of Nestin expression and up-regula-
tion of the astrocyte markers Aqp4 and Gfap. Of note,
FOXG1/SOX2-bound targets that showed altered expres-
sion 4 d after Dox treatment and return to self-renewal
medium (EGF/FGF-2) included core regulators of the
cell cycle (Plk1, Foxo3, and Mycn) and epigenetic pro-
cesses (Dnmt1 and Tet3) (Fig. 4D). Foxo3 expression
was one of the most significantly up-regulated genes after
24 h of BMP treatment and was down-regulated upon
treatment with Dox and exposure to EGF/FGF-2. Foxo3
is a well-established negative regulator of cell proli-
feration downstream from the PI3K signaling pathway.
FOXG1/SOX2-bound regions included the proximal
promoter and a conserved intronic element (CIE) harbor-
ing multiple motifs for SOX and FOX (Fig. 5C). We there-
fore pursued this as a candidate functionally important
target.
Transcriptional repression of Foxo3 by FOXG1/SOX2
removes a barrier to astrocyte cell cycle re-entry
Foxo3 has an established role in NS cell homeostasis and
quiescence (Webb et al. 2013), and a recent study suggests
that it is directly regulated by Foxg1 (Vezzali et al. 2016).
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Figure 4. ChIP-seq of FOXG1 targets in mouse NS cells. (A) FOXG1-V5 ChIP-seq identifies 6897 binding peaks conserved across two
separately derived mouse NS cell lines (Foxg1 ChIP mm10.bed). Motif analysis within the ChIP-seq peak regions for FOXG1-V5 reveals
enrichment for the forkhead box motif as well as HLH, NF1–CTF, and HMG-box motifs. (B) There is extensive overlap between FOXG1-
and Sox2-bound regions, with 3856 of 6897 FOXG1-bound regions also exhibiting Sox2 binding. (C ) Shared bound regionswere assigned to
gene loci using the Stanford University genomic regions of enrichment annotations tool (GREAT; FOXG1_Sox2 intersect gene associa-
tions.txt) and were found to be enriched for the GO terms shown (FOXG1_Sox2 intersect gene ontology.tsv). (D) RNA-seq demonstrates
that Foxo3 is up-regulated after BMP4 treatment, along with astrocytemarkersGfap andAqp4; in contrast,Nestin and epigenetic remod-
eling machinery Tet3 and Dnmt1 are down-regulated. NS cell expression patterns return by day 14 (+Dox).
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Figure 5. FOXG1/SOX2 forced expression drives reduced expression of Foxo3, and genetic ablation of Foxo3 removes a barrier to cell
cycle re-entry. (A) RNA-seq data for Foxo3 following return to EGF/FGF-2 for 1 or 4 dwith or withoutDox. (FPKM) Fragments per kilobase
of transcript per million mapped reads. (B) ICC for FoxO3 protein in FS3 cells plated at clonal density after 24 h in EGF/FGF-2, 24 h in
BMP4, and return to EGF/FGF-2 for 4 dwith orwithoutDox. (C ) The Foxo3 locus is bound by FOXG1 and Sox2 at both the promoter region
and a CIE (indicated by red box). (Top) These regions enrich for H3K27 acetylation, a marker of active promoters and enhancers, and dem-
onstrates high conservation across mammalian species (PhyloP). Clusters of the AAACA sequence comprising part of both Forkhead- and
Sox-binding motifs are indicated by red arrowheads. Guide RNAs flanking the CIE were selected with a view to excision of this region by
CRISPR/Cas9 (blue rectangles), along with sequencing primers for genotyping the resulting clones (yellow rectangles). (D) PCR genotyp-
ing to confirm biallelic deletion with the expected single band in one line (termed FID11); FID11 retains the ability to respond to Dox and
hence induce FOXG1-V5 expression, as determined by ICC (below). (E) Deletion of the FOXG1/SOX2-boundCIE results in derepression of
Foxo3 mRNA expression in NS cell proliferation conditions. n = 3. (∗) P < 0.02). (F ) Colony formation following Dox-induced FOXG1/
SOX2 expression is abolished in CIE-deleted cells. Mean ± SEM. (G) Western blot confirming the absence of FoxO3 protein expression
in FOD3, a clonal cell line harboring a frameshift insertion–deletion (indel) mutation on the nontargeted allele. (H) Following BMP treat-
ment, Foxo3−/− FOD3 cells divide slowly in growth conditions (doubling time ∼6 d), in contrast to Foxo3+/+ controls, which remain cycle-
arrested. FOXG1/SOX2 induction or treatment of FOD3 cells with 5-azacytidine (5-Aza) drives rapid colony formation and proliferation to
confluence (doubling time ∼24 h). (I ) Colony-forming assay at 10 d for dedifferentiation responses in Foxo3−/− cells and those treatedwith
5-Azawith andwithout Dox. (J) ICC for Nestin andGfap. The proportion of cells positive for nestin in representative colonies is indicated
below the panels. See also Supplemental Figure S5D.
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Our own RNA-seq data indicated a rapid up-regulation
of Foxo3mRNA following BMP-induced astrocyte differ-
entiation (Fig. 4D). Levels of Foxo3mRNAare reduced fol-
lowing addition of Dox and a switch to NS cell medium
(Fig. 5A). Immunocytochemistry (ICC) for Foxo3 protein
confirmed up-regulation and nuclear translocation fol-
lowing BMP treatment (Fig. 5B). ChIP-seq data indicated
binding of both FOXG1 and SOX2 at a highly conserved
intronic element within Foxo3 (Fig. 5C). This region con-
tains multiple repeats of the sequence AAACA, which
comprises part of binding motifs for FOX and SOX TFs
in NS cells (Lodato et al. 2013).
To directly test the functional significance of binding
at the Foxo3 CIE, we took advantage of CRISPR/Cas9
genome editing, which we optimized for mouse and hu-
man NS cells (Bressan et al. 2017). Using a pair of guide
RNAs (gRNAs), we deleted the 780-base-pair (bp) Foxg1/
Sox2-bound CIE in FOXG1/SOX2-overexpressing FS3
cells (Fig. 5C). Subclones were identified in which both al-
leles were disrupted (Fig. 5D). Deletion of this element led
to increased levels of Foxo3mRNA expression under self-
renewal conditions (EGF/FGF-2) (Fig. 5E), and prolifera-
tion of this line was marginally slower (data not shown).
Importantly, these cells were now unable to undergo
dedifferentiation in response to FOXG1/SOX2 overexpres-
sion (Fig. 5F). We surmise that this regulatory element is
critical in enabling FOXG1/SOX2 to repress Foxo3 expres-
sion, thereby removing a critical blockade to cell cycle
re-entry.
To confirm the potential relevance of these findings to
human GBM, we performed ChIP-seq for FOXG1 in four
independent human GNS cell lines (G7, G14, G25, and
G166) using a newly generated antibody against endoge-
nous FOXG1. Although less specific than V5 ChIP, we
identified a total of 7499 peaks and noted strong enrich-
ment for the forkhead box and relatedmotifs (Supplemen-
tal Fig. S5A). These data showed that FOXG1 was bound
to the FOXO3 CIE (Supplemental Fig. S5B).
Reacquisition of the proliferative NS cell state can
be achieved by combined loss of Foxo3 and alterations
to DNA methylation
To test the consequences of Foxo3 deletion, we excised
exon 2 of Foxo3 in FS3 cells using CRISPR/Cas9-assisted
gene targeting (Bressan et al. 2017). Biallelic mutant lines
were generated through simultaneous replacement of one
Foxo3 allele with an EF1a-puromycin resistance cassette
and insertion–deletion (indel)mutations on the remaining
allele (Supplemental Fig. S5C). Foxo3 protein was unde-
tectable in a clonal line that contained a frameshift indel
mutation and generated a nonsense product (FOD3) (Fig.
5G). These FOD3 Foxo3−/− mutant cells retained a re-
sponsiveness to BMP treatment similar to that of their
parental cells, with concomitant up-regulation of astro-
cyte markers (including Gfap) and acquisition of the char-
acteristic morphology (data not shown). However, in
contrast to parental controls, which exited cell cycle,
Foxo3 mutant cells proliferated slowly on re-exposure to
EGF/FGF-2 without Dox (doubling time of ∼6 d) (Fig.
5H). Thus, Foxo3 ablation sensitizes astrocytes to growth
factors and relieves a barrier to cell cycle re-entry. Impor-
tantly, however, these cells did not fully dedifferentiate
and retained Gfap expression (Fig. 5H–J). They remained
slow-cycling. We conclude that cell cycle entry and differ-
entiation status are uncoupled in the context of Foxo3
deletion. Additional target genes are therefore required
to trigger dedifferentiation and rapid proliferation.
We reported previously that humanGBM stem cells fail
to undergo terminal differentiation commitment and
have aberrant DNA methylation patterns in response to
BMP treatment (Carén et al. 2015). Shared transcriptional
targets of FOXG1/SOX2 included several regulators of
DNA and histone methylation. These genes represent
clear candidates that might be involved in destabilizing
astrocyte differentiation. Inhibition of DNAmethyltrans-
ferase activity by the nucleoside analog 5-azacytidine (5-
Aza) has been reported to facilitate induced pluripotent
stem cell reprogramming (Mikkelsen et al. 2008). We
therefore hypothesized that Dnmt inhibition by 5-Aza
might facilitate dedifferentiation by interfering with the
establishment or maintenance of the DNA methylation
profile in differentiating astrocytes. Indeed, either 5-Aza
or ascorbic acid (a cofactor for Tet proteins) could trigger
increased proliferation in populations of Foxo3 mutant
astrocytes (Supplemental Fig. S5D). This was quantified
for 5-Aza using colony formation assays for the slow-cy-
cling BMP-treated Foxo3 mutants (FOD3). Strikingly,
the combination of 5-Aza treatment with Foxo3 deletion
resulted in the emergence of rapid-cycling populations
forming numbers of Nestin-positive colonies similar to
the Dox-treated FS3 cultures (Fig. 5H–J). Thus, 5-Aza in
combination with loss of Foxo3 can phenocopy the effects
of FOXG1/SOX2 induction. Resetting of DNA methyla-
tion patterns that are acquired during astrocyte differenti-
ation may therefore be a critical feature of FOXG1/SOX2
reprogramming activity.
FOXG1 overexpression affects multiple regulators
of DNA methylation to facilitate dedifferentiation
We next investigated the effect of forced expression of
higher levels of FOXG1 or SOX2 alone using the F6
and S15 lines, respectively (Supplemental Fig. S2E,F).
Each of these lines enabled higher levels of each individual
factor to be expressed in differentiating astrocytes. High
levels of induction of FOXG1 alone, but not SOX2, were
sufficient to drive efficient colony formation in two
independent FOXG1-inducible lines (F6 and F11) (Fig.
6A,B). The resulting dedifferentiated cells displayed
morphology, proliferation kinetics, and marker expres-
sion similar to the parental line and responded to BMP-in-
duced differentiation (Supplemental Fig. S6A,C–E). RNA-
seq confirmed that these cultures were reacquiring NS
cell-like transcriptional signatures, and many of the acti-
vated genes included FOXG1/SOX2-bound genes (Fig.
6C). We confirmed by RNA-seq and quantitative RT–
PCR (qRT–PCR) that there is a significant increase in ex-
pression ofDnmt1,Dnmt3b, andTet3 following increased
FOXG1 expression (Fig. 6D; Supplemental Fig. S6B).
Elevated FOXG1/SOX2 drives NS cell identity
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Figure 6. FOXG1 overexpression results in increased activation of regulators of DNAmethylation, and these may affect key polycomb
target genes. (A) Colony numbers upon return to self-renewal medium with or without 1000 ng/mL Dox for 10 d following 24 h of BMP4
treatment. Induction of FOXG1 alone in two independent lines (F6 and F11) induced colony formation at higher efficiency than in FS3.
Induction of SOX2 alone (TS15) was not sufficient to drive colony formation. (B) Example of a colony-forming assay for F6 showing col-
onies after 10 d in EGF/FGF-2 only on the addition of Dox. (C ) RNA-seq confirms that, following FOXG1 induction byDox, BMP4-treated
F6 cells reacquire anNS cell-like transcriptional signature. (Left) Alignmentwith ChIP-seq data for FOXG1 and SOX2 indicates thatmany
of the genes activated on dedifferentiation are bound by FOXG1 and SOX2. (D) qRT–PCR analysis ofDnmt1,Dnmt3b, and Tet3. Mean ±
SD. n = 4. Significance was assessed by two-way ANOVA with Bonferroni post-hoc test. (∗∗) P≤ 0.01; (∗∗∗) P≤ 0.001; (∗∗∗∗) P≤ 0.0001. (E)
Analysis of enrichment of reduced representation bilsulfite sequencing (RRBS) identified differentially methylated regions (DMRs) near
genes marked by polycomb in mouse embryonic stem (ES) cells, NS cells, and brains. Shown is the percentage of CpGs assayed by RRBS
found near polycomb-marked genes (background, gray) compared with those in significant DMRs after either 24 h or 10 d of differentia-
tion. (Blue) BMP-increased methylation; (orange) BMP-decreased methylation. Significance was assessed with Fisher’s exact tests (∗∗) P <
0.01; (∗∗∗) P < 0.001.n = 3. (F )Meanmethylation profiles observed byRRBS in the Foxo3 promoter, including the locations of its CpG island
(CGI) and Foxg1 ChIP-seq peak. Significant DMRs are shown in red together with an additional DMR that did not reach statistical signifi-
cance in all replicates of the experiment (pale red).
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DNA methylation changes at polycomb target genes,
including Foxo3, occur during astrocyte differentiation
To define the DNAmethylation changes that accompany
BMP-induced astrocyte differentiation, we performed re-
duced representation bilsulfite sequencing (RRBS). Analy-
sis of the resulting methylation profiles identified a total
of 3231 significantly differentially methylated regions
(DMRs) after 24 h or 10 d of BMP-induced differentiation
(756 with reduced methylation and 2475 with increased
methylation). These DMRs were significantly enriched
near developmental TFs (Supplemental Fig. S6F). Devel-
opmental TFs are known to be regulated by polycomb-re-
pressive complexes; indeed, BMP-induced DMRs were
enriched near polycomb-repressive complex target genes
previously reported in mouse NS cells, embryonic stem
cells, and brains (Fig. 6E; Meissner et al. 2008). This in-
cluded methylation changes at the promoter of Foxo3
close to a Foxg1-binding site (Fig. 6F). These analyses sug-
gest thatDNAmethylation changes occur at developmen-
tal TFs during astrocyte differentiation and that FOXG1
may help in reconfiguring these during dedifferentiation
via its control ofmultiple regulators of DNAmethylation.
Genetic ablation of FOXG1 in human GNS cells does
not affect in vitro proliferation, but SOX2 is essential
Previous studies using shRNA knockdown of FOXG1
have suggested an important role in promoting tumor
growth (Verginelli et al. 2013). CRISPR/Cas9 provides
new opportunities for decisive functional genetic studies
in primary human GBM stem cells. Using recently opti-
mized protocols (Bressan et al. 2017), we next performed
gene targeting via homologous recombination to delete
FOXG1 in human primary GNS cells (G7) (Supplemental
Fig. S7A). One of the resulting clonal lines (G7-A) har-
bored a 23-bp frameshift insertion at the second allele
and demonstrated loss of FOXG1 protein by immunoblot-
ting (Fig. 7A; Supplemental Fig. S7A). In contrast to previ-
ously reported findings using tumor sphere models, we
found no discernible effect of FOXG1 ablation on prolifer-
ation rates of GNS cells in vitro (Fig. 7B).
We next compared the FOXG1 loss-of-function pheno-
type with SOX2 loss in G7 cells. Previous studies have
suggested that Sox2 is required for self-renewal of fore-
brain NS cells: Homozygous knockout by conditional
deletion or CRISPR/Cas9 targeting is incompatible with
colony formation (Gómez-López et al. 2011; Bressan
et al. 2017). Here, CRISPR/Cas9 was used to mutate the
single coding exon of SOX2 (Supplemental Fig. S7B). We
were unable to recover expandable SOX2 mutant clones,
suggesting that these may have a proliferation defect.
The proportion of SOX2-negative cells was tracked in
the primary transfected population over time by ICC (Sup-
plemental Fig. S7C–E). Approximately 25% of mutant
cells were detectable in the transfected population at
day 7; however, by day 14 and day 42, this subpopulation
had dropped to ∼18% and <1% of the population, respec-
tively. Coculture with the nondeleted wild-type cells
clearly could not rescue the proliferation defect. We con-
clude that loss of SOX2 ablates the proliferative capacity
of patient-derived GBM cells in a cell-autonomous man-
ner. This is in contrast to FOXG1, which is dispensable
for in vitro NS cell proliferation.
FOXG1 mutant human GNS cells are sensitized
to cytostatic signals in vivo and up-regulate FOXO3
To test the consequences of FOXG1 loss in vivo, we
transplanted cells orthotopically into the brains of im-
munocompromised mice. A GFP reporter construct
was inserted at the safe harbor AAVS1 locus in both
parental control cells and the FOXG1−/− clone to enable
monitoring of cells following xenotransplantation. Con-
sistent with the previously reported shRNA knock-
down results (Verginelli et al. 2013), we saw a failure of
the FOXG1−/− G7-A cells to form tumors on transplan-
tation into immunocompromised mice (n = 4) (Fig. 7C).
We hypothesized that FOXG1 is able to protect cells
from prodifferentiation signals that would trigger exit
from the cell cycle in vivo.
Our findings in mouse NS cells suggested that FOXG1
operates in part by helping repress FOXO3, and this could
be a key effector of its function by limiting astrocyte dif-
ferentiation. We therefore assessed expression of GFAP
and FOXO3 in the FOXG1 knockout cells following trans-
plantation in vivo. The transplanted cells were present
at the injection site, and these were found to express
high levels of GFAP and FOXO3 and low levels of Ki67
compared with wild-type controls. They also displayed
morphological features of differentiated “star-shaped” as-
trocytes (n = 4) (Fig. 7D–H). This indicates that FOXG1 is
required to sustain GNS cell growth in vivo. In conclu-
sion, we found that SOX2 is essential for continued prolif-
eration of GBM stem cells, while FOXG1 is not. However,
increased levels of FOXG1 safeguard the stem cell state
from prodifferentiation cues encountered outside the en-
dogenous SVZ niche. This restriction of differentiation
commitment is mediated at least in part through repres-
sion of negative regulators of proliferation such as
FOXO3. (Fig. 7I).
Discussion
There are important conceptual and mechanistic similar-
ities between cellular transformation in human cancers
and cellular reprogramming (Suvà et al. 2013). FOXG1
and SOX2 are key regulators of forebrain neural progenitor
fate and are known reprogramming factors (Lujan et al.
2012). Here we demonstrated that high FOXG1 and
SOX2 levels, a consistent feature of GNS cells, are func-
tionally important in driving a highly proliferative,
growth factor-responsive, radial glia-like NS cell state.
These master regulators operate through transcriptional
control of various stem cell-associated pathways, most
notably cell cycle and epigenetic regulators. Cancer
stem cells therefore deploy overexpression of key line-
age-affiliated TFs as a mechanism to fuel their self-renew-
al—the same strategy used by stem cell biologists in
experimental reprogramming.
Elevated FOXG1/SOX2 drives NS cell identity
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FOXG1 is consistently up-regulated across all GNS
cells that were assessed. Using ATAC-seq profiling of hu-
man GNS and NS cells, we identified an enrichment of
open regions containing many neurodevelopmental TF
motifs, including binding sites of SOX and FOX TF fami-
lies. This supported our hypothesis that increased levels
of FOXG1 and SOX2 might be important in driving
GBM cell self-renewal and is consistent with the known
roles of these factors during development of the mamma-
lian forebrain (Xuan et al. 1995).
We initially explored Foxg1 loss of function using a new
conditional NS cell line. Mutant cells become sensitized
to differentiation cues, but, surprisingly, therewas no pro-
liferative defect in vitro. This is in contrast to loss of Sox2,
which has been shown previously to be a critical factor for
proliferation of mouse NS cells. This suggested to us that
the gain-of-function phenotype for Foxg1 is more critical,
and its role might be specifically in limiting terminal dif-
ferentiation commitment or driving dedifferentiation. A
quantitative colony formation assay was developed to
Figure 7. Genetic ablation of FOXG1 in humanGBMstemcells usingCas9-assisted gene targeting. (A) CRISPR/Cas-based gene targeting
was used to knock out FOXG1 inG7 cells, and no proteinwas detectable byWestern blot, with a frameshiftmutation demonstrated on the
second FOXG1 allele in this clone (see Supplemental Fig. S7). (B) Growth curve displaying percentage confluence over time for G7 andG7
FOXG1−/− cell lines, indicating that the FOXG1−/− clone proliferates at a rate similar to that of parental controls in vitro. (C ) Upon xe-
notransplantation, wild-type G7 cells expressing a GFP reporter form invasive tumors, but FOXG1−/− derivatives fail to do so. n = 4 for
each cell line. (D) Immunohistochemistry (IHC) analysis of xenografts reveals that the G7 FOXG1 mutant cells display increased expres-
sion of astrocyte markers S100β (red) and GFAP (gray), reduced expression of NESTIN (gray) (E), increased expression of FOXO3 (F ), and
decreased expression of Ki67 (red) (G). (H) Quantitation of the percentage of cells positive for GFAP, Ki67, and FOXO3 from IHC. (I ) Work-
ing model of FOXG1 and SOX2 function in GBM based on this study. (Green cell) Post-mitotic or quiescent astrocytes; (brown/gray cell)
radial glia-like proliferative NS cell. Bar, 10 µm; bar for higher-magnification images in F, 20 µm. Students t-test, n = 4; P < 0.005.
Bulstrode et al.
768 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on June 7, 2017 - Published by genesdev.cshlp.orgDownloaded from 
explore the consequences of increased expression of hu-
man FOXG1 and SOX2 in dedifferentiating astrocytes,
thereby mimicking the increased levels of FOXG1 seen
in GBMs. We did not observe increased levels of SOX2
protein in GNS cells compared with NS cells. However,
unlike FOXG1, SOX2 is amplified in GBM. It is possible
that the levels of SOX2 in NS cells are already saturating
in vitro. We found that NS cells plated at low density
and treated with BMP4 for 24 h exit cell cycle with acqui-
sition of astrocyte morphology and markers. Quiescent
NS cells in vivo express Gfap. So, are we modeling the
transition from quiescence to reactivation/proliferation
or terminal differentiation to dedifferentiation? We could
induce NS cell colony formation by FOXG1/SOX2
induction when using fresh primary postnatal astrocyte
preparations. Furthermore, we found recently that low-
density BMP-treated astrocytes have reduced levels of qui-
escent stem cell astrocyte markers (data not shown). A
key functional criterion for distinguishing quiescent as-
trocytes and differentiating astrocytes is that the latter
cannot be driven into cycle when re-exposed to EGF/
FGF-2. Thus, we view our assay as a dedifferentiation
response.
Our ChIP-seq data for FOXG1 and the intersection with
SOX2-bound sites suggested that these factors have com-
mon target genes, including both important core cell cycle
and epigenetic regulators. However, we found no indica-
tion of physical interaction between SOX2 and FOXG1us-
ing protein coimmunoprecipitation (data not shown).
This is consistent with characterized SOX2 protein part-
ner analysis in mouse NS cells (Engelen et al. 2011). Rath-
er, it seems likely that FOXG1 and SOX2 are cooperating
indirectly at the gene regulatory network level.
Exposure to Dox and EGF/FGF-2 triggered a relatively
rapid emergence of proliferating colonies, whether from
NS cell-derived in vitro generated astrocytes or astrocytes
from primary cultures. Inspection of this response by
time-lapse imaging together with the sizes of resulting
colonies suggested that cell cycle re-entry was an early
event.We recognized thatmultiple targets will contribute
to the potency of FOXG1/SOX2 activity and searched for
those candidates that might have a major contribution.
Foxo3, which has an established role inNS cell homeosta-
sis and quiescence, emerged as a functionally important
transcriptional target of FOXG1/SOX2. This finding
is consistent with Foxo3 as a transcriptional target of
Foxg1 during telencephalic development (Vezzali et al.
2016). FOXO3 activity is also known to be affected by in-
teraction with FOXG1 at the protein level (Seoane et al.
2004); FOXG1 therefore exerts a dual inhibition of
FOXO3 activity: at the protein–protein level and through
transcriptional suppression. We used CRISPR/Cas9 ge-
netic ablation to confirm FOXG1 repression of Foxo3 at
the transcriptional level. Importantly, in the absence of
the FoxG1-bound repressive element in the Foxo3 intron,
NS cells could no longer respond to Dox. Therefore, tran-
scriptional repression of Foxo3 through this site may be
the primary mechanism of control by FoxG1, with the
sequestration through protein–protein interaction being
an added layer of regulatory control.
Foxo3 ablation removes a barrier to cell cycle re-entry;
however, the mutant cells retained astrocyte morphology
and high GFAP expression and displayed slow proli-
feration kinetics on the restoration of growth factors fol-
lowing BMP treatment. Foxo3 repression alone is
therefore insufficient to trigger full dedifferentiation to
anNS cell-like state. Additional targets must exist. Given
the prominence of methyltransferase and histonemethyl-
transferase complexes in GO analysis of the FOXG1/
SOX2-bound regions, we explored whether resetting of
DNA methylation patterns could remove a barrier to
dedifferentiation. This proved to be the case, as a short
24-h pulse of a low dose of 5-Aza (a nucleoside analog
that inhibits DNAmethyltransferase activity) or ascorbic
acid (a cofactor of the TET family of enzymes that trigger
DNA demethylation) was sufficient to stimulate rapid
proliferation of Foxo3 mutant cells. Thus, the effects
of FOXG1/SOX2 overexpression can be phenocopied by
removal of Foxo3 and reconfiguration of DNA methy-
lation patterns. Multiple regulators of DNA methyla-
tion were bound by FOXG1, including Tet3, Dnmt3b,
and Dnmt1. These displayed changes in expression
upon Dox treatment in FOXG1-alone-overexpressing
cells (F6).
DNA methylation profiling using RRBS identified sig-
nificant methylation changes in astrocytes following 24
h of BMP4 treatment that were heavily enriched for poly-
comb target genes, including Foxo3. Unfortunately, as
only a subpopulation of the cells undergoes dedifferentia-
tion following re-exposure to growth factors and addition
of Dox, wewere unable to identify any significant changes
in methylation after 4 d (data not shown). Future studies
will require isolation/enrichment for the earliest dediffer-
entiating cells to define the specific link between key sites
of methylation changes and FOXG1 binding. Tet3 is a
clear candidate that might impact the stability of the
methylome in differentiating astrocytes. Our current
data support a model in which high levels of FOXG1/
SOX2 have at least two complementary activities: stimu-
lation of core cell cycle regulators and triggering of epige-
netic resetting to drive post-mitotic astrocytes into the
more immature radial glial-like NS cell state (Fig. 7I). Fur-
ther definition of the downstream targets of these factors
might uncover “druggable” targets and guide rational
combination therapy strategies.
Not all astrocytes are able to respond to FOXG1/SOX2.
It is possible that additional factors or signaling pathway
manipulations could improve efficiency. There might
also be some stochastic element to triggering dedifferen-
tiation, as is the case with induced pluripotent stem cell
reprogramming (Buganim et al. 2012). Other noteworthy
annotated gene sets that we identified via ChIP-seq anal-
ysis included mitochondrial function, Notch, and Wnt/
β-catenin signaling. Many of these have been implicated
in the growth of GBMs, and further studies will be needed
to define whether these can enhance dedifferentiation.
Using CRISPR/Cas9 gene targeting, we were able to
genetically ablate FOXG1 in primary human GBM stem
cells. FOXG1 is dispensable for in vitro NS cell proli-
feration when cultured in adherent conditions with
Elevated FOXG1/SOX2 drives NS cell identity
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EGF/FGF-2. This seemingly contradicts previous shRNA
knockdown studies that concluded that FOXG1 is re-
quired to sustain proliferation (Verginelli et al. 2013).
However, Verginelli et al. (2013) assayed proliferation us-
ing tumor spheres, a condition in which spontaneous dif-
ferentiation can occur. Thus, the discrepancy is likely
explained by differences in culture regimes. These find-
ings are also consistent with the fact thatwe can routinely
derive NS cell lines from different regions of the develop-
ing nervous system (midbrain, hindbrain, and spinal cord)
that do not express FoxG1 either in vivo or in vitro. Thus,
FOXG1 is not an essential cell cycle driver in NS cells;
rather, it is required to protect cells from prodifferentia-
tion cues and can trigger the transition out of the nonpro-
liferative state.
Previous studies have explored the core transcriptional
circuits that might be exploited by GBM stem cells. A re-
programming cocktail incorporating SOX2, OLIG2, and
POU3F2 has been used to reinstate tumorigenicity in “dif-
ferentiated” glioblastoma cells (Suvà et al. 2014), and this
network was generated by focusing on TFs differentially
expressed between GBM stem cells and serum-induced
differentiating progeny. FOXG1 was not among the fac-
tors comprising the core transcriptional circuit identified
in these studies. However, a recent study by the Barres lab-
oratory (Zhang et al. 2016) has identified genes differen-
tially expressed between immature fetal astrocytes and
post-mitotic adult cortical astrocytes. FOXG1 is indeed
one of the most differentially expressed genes (Supple-
mental Fig. S7F). We speculate that up-regulation of
FOXG1 expression is a critical event in the emergence
of GBM, occurring either early in tumorigenesis to pro-
duce primary glioblastoma or later, resulting in secondary
transformation of a low-grade glioma. In keeping with
this, we found variable FOXG1 expression in a panel of tu-
mor lines derived from World Health Organization grade
II and grade III gliomas (data not shown).
In conclusion, we show that elevated FOXG1 plays a
functionally important role in limiting differentiation
commitment. SOX2 is required to sustain NS and GNS
cell proliferation. When coexpressed, these two activities
drive self renewal and enforce a proliferative radial glial-
likeNS cell state. Althoughwe found no evidence of a pro-
tein level interaction between these factors, they share
multiple core cell cycle and epigenetic regulatory targets.
Our findings highlight the increasing evidence in support
of a critical role for neurodevelopmental TFs in driving
unconstrained self-renewal in GBM.
Materials and methods
Cell culture
Mouse and humanNS andGNS cell lineswere derived fromadult
SVZ, fetal cortex, or primary glioblastoma specimens as de-
scribed previously (Conti et al. 2005; Sun et al. 2008). Established
lines were cultured in serum-free basal medium supplemented
with N2 and B27 (Life Technologies), 1 mg/mL laminin (Sigma),
and 10 ng/mL growth factors EGF and FGF-2 (Peprotech). Medi-
um was changed every 3 d, and cells were split typically once
per week after dissociation with Accutase solution (Sigma) and
centrifugation.
BMP treatment comprised plating dissociated NS cells at low
density (10 cells per squaremillimeter) inmedium supplemented
with 10 ng/mL BMP4 (Peprotech) in place of EGF/FGF-2. After 24
h, this was replaced by standard growthmedium containing EGF/
FGF-2. Colonies were stained with ethidium bromide and visual-
ized under UV light.
IENS cells, described previously (Bruggeman et al. 2007), were
kindly provided byM. Van Lohuizen (Nederlandse Kappersakade-
mie, Amsterdam). Supplemental Table 1 details the mouse NS
cell line derivatives established here and summarizes their differ-
entiation/dedifferentiation characteristics. Growth curves were
generated using an IncuCyte live-cell imaging system.
Primarymouse astrocyte cultures were prepared from the tryp-
sin-digested cortical plate tissue of postnatal day 3 (P3) mouse
cortices (strainMF1), according to established protocols (Schildge
et al. 2013), including shake-off after 1 wk to remove contaminat-
ing microglia and progenitor cells.
Derivation of stable transgenic and knockout cell lines
Onemillion cells were transfected with the AmaxaNucleofector
system using either the X005 pulse protocol (human cells) or T-
030 protocol (mouse cells).
For inducible transgene overexpression, a total of 6 µg of DNA
was supplied, comprising piggyBac transposase pBASE, pCAG-
rtTA(Tet3G), and pDEST-TetOn vector in 1:1:2 ratios. For
CRISPR targeting, gRNAs (times two), targeting vector (where ap-
propriate), and Cas9 nickase were transfected in a 1:1:1:2 ratio.
Cells were plated in 10-cm dishes, with Dox added after 24 h
where appropriate, and selection commenced 48 h after transfec-
tion using 5 µg/mLblasticidin, 1 µg/mL puromycin, or 100 µg/mL
hygromycin. Each of these antibiotics produced uniform cell
death within 7 d in untransfected mock controls (both human
NS and GNS cells).
G7 primary humanGNS cells were transfectedwithCas9 nick-
ase, gRNAs corresponding to the forkhead domain of the FOXG1
locus, and a targeting vector comprising an EF1a-puromycin anti-
biotic resistance cassette flanked by 1-kb homology arms specific
for the locus.
ICC
Cells were washed with PBS and fixed using 4% paraformalde-
hyde for 10 min at room temperature. Samples were incubated
overnight with primary antibodies in blocking solution (PBST +
3% goat serum and 1% BSA) followed by incubation with appro-
priate secondary antibodies and 4′,6-diamidino-2-phenylindole
(DAPI). Images were obtained using a Zeiss Observer Z1 micro-
scope and AxioVision software or a PerkinElmer Operetta high-
content imaging system and Harmony software. Transplanted
mouse brains were harvested, sectioned into 30-µm slices using
a vibratome, stained using immunohistochemistry (IHC) as
free-floating staining, and imaged using a Leica SP8 confocal
microscope.
The following primary antibodies were used: Olig2 (1:100;
Millipore), V5 tag (1:1000; eBioscience), Sox2 (1:50; R&D Sys-
tems), mNestin (1:10; Developmental Studies Hybridoma
Bank), hNestin (1:500; R&D Systems), FOXG1 (1:3; hybridoma
clone 17B12), FOXO3 (1:800; Cell Signaling Technology), GFAP
(1:1000; Sigma), S100 (1:100; DAKO), Stem121 (1:500; Stem
Cell Technology), BLBP (1:200; Santa Cruz Biotechnology), and
Ki67 (1:500; Lab Vision). EdU incorporation assays were per-
formed as described previously (Carén et al. 2015).
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Western immunoblotting
Immunoblotting was performed using standard protocols. Anti-
bodies were diluted in 5% milk powder in PBS Triton 0.1%,
and protein detection was carried out with HRP-coupled second-
ary antibodies and X-ray films. The following primary antibodies
were used: FOXG1 (1:15; hybridoma clone 17B12), SOX2 (1:400;
R&D Systems), GAPDH (1:1000; GenTex), and V5 tag (1:1000;
eBioscience).
qRT–PCR and low-density arrays (LDAs)
RNA extraction was performed using the Qiagen RNeasy Plus
minispin column kit, eluting in 50 µL of RNase-free water,
and using an additional DNase step. RNA concentration was
determined using theQubit RNAHigh-Sensitivity kit (Life Tech-
nologies). Reverse transcription was performed using the Invi-
trogen SuperScript III kit according to the manufacturer’s
instructions. TaqMan qPCR and TaqMan LDA card assays were
performed using TaqMan Universal PCR Master Mix and assays
(Applied Biosystems) according to the manufacturer’s guidelines.
Resultswere normalized to the housekeeping geneGapdh and an-
alyzed with HTqPCR (Dvinge and Bertone 2009). The following
TaqMan assays were used: mGapdh (Mm99999915_g1), mFoxG1
(Mm02059886_s1), mFoxo3 (Mm01185722_m1), mGfap (Mm012
53033_m1), mAqp4 (Mm00802131_m1), mS100b (Mm00485
897_m1), mNestin (Mm00450205_m1), mOlig2 (Mm0121055
6_m1), mBlbp (Fabp7) (Mm00445225_m1), mSox2 (Mm03053
810_s1), mDnmt1 (Mm01151063_m1), mDnmt3b (Mm012
40113_m1), mTet3 (Mm00805756_m1), and hGAPDH (Hs027
58991_g1).
RNA-seq library construction
RNA-seq libraries were prepared from 100 ng of mRNA extracted
usingQiagen RNeasy kits. Library preparationwas conducted us-
ing NEBNext mRNA reagents (E6100) and multiplex indices for
Illumina (E7335).
ChIP-seq library construction
Chromatin was prepared and immunoprecipitation was under-
taken according to protocols described previously (Sofueva et al.
2013). Sonication was performed in 0.7% SDS using a Diagenode
Bioruptor (maximum power 30 sec on and 30 sec off for 45 min).
Pull-down was undertaken using Dynabead protein G sepharose
beads (Thermo Scientific) conjugated with 10 µL of ChIP-grade
antibody (anti-FoxG1 [Abcam, ab18259] and anti-V5 [Abcam,
ab15828]) diluted in 250 µL of buffer.
ATAC-seq library construction
ATAC-seq libraries were prepared using Illumina Nextera re-
agents as described (Buenrostro et al. 2013), with PCR amplifica-
tion and indexing using published sequencing adapter primer
sequences supplied as oligonucleotides (Sigma) (Buenrostro
et al. 2013).
ChIP-seq data analysis
Filtered read files were imported to the Galaxy Web-based analy-
sis portal. Within Galaxy, the files were parsed into Sanger FastQ
format, and then each read was truncated from 100 to 55 bp (base
pairs 10–65 of the original read). The read files were eachmapped
to the mouse genome (mm9 assembly) using Bowtie conFig.d
with default parameters. The resulting BAM alignment files
weremerged into a single file, and peak calling was performed us-
ing the MACS 2.0 algorithm. Galaxy was also used to determine
motif enrichment (SeqPosMotif tool), and the Stanford Universi-
ty genomic regions of enrichment annotations tool (GREAT ver-
sion 3.0.0) was used for target gene and ontology analysis.
ATAC-seq data analysis
ATAC-seq data were normalized and compared as described pre-
viously (Carén et al. 2015), with the exception of motif analysis,
whichwas applied toGNS-enriched loci using all accessible chro-
matin sequences as a control. Heat maps were generated from
CQN-normalized data using the Euclidean distance metric and
Ward’s method for clustering the rows.
RRBS library preparation
gDNAwas isolated from F6 cells using the MasterPure complete
DNA purification kit (Epicentre) from three independent experi-
ments and concentrated with the TM-5 DNAClean and Concen-
trator kit (Zymo Research) before being quantified by Qubit
dsDNA BR assay and Nanodrop. Eighty-five nanograms of each
purified DNA sample was processed using the Ovation RRBS
Methyl-Seq system kit (NuGEN Technologies). Unmethylated
phage λDNA (0.5 ng) was spiked into each sample to allow assess-
ment of bisulfite conversion efficiency. Briefly, the methylation-
insensitive restriction enzyme MspI was used to digest the
gDNA, and digested fragments were ligated to adapters. Adapt-
er-ligated fragments were then repaired before bisulfite conver-
sion with the EZ DNA Methylation-Lightning kit (Zymo
Research). Bisulfite-treated adapter-ligated fragments were am-
plified by 15 cycles of PCR and purified using Agencourt RNA-
Clean XP beads. Libraries were quantified using the Qubit
dsDNA HS assay and assessed for size and quality using the Agi-
lent Bioanalyzer DNA HS kit. Sequencing was performed using
the NextSeq 500/550 high-output version 2 kit (150 cycles; Illu-
mina) on the NextSeq 550 platform. Libraries were combined
into equimolar pools and run across four flow cells. Library prep-
aration and sequencingwere performed at the Edinburgh Clinical
Research Facility.
Intracranial xenotransplantation
Transplantswere performed as described previously (Pollard et al.
2009). Briefly, we used a stereotaxic frame to inject 100,000 cells
in 1 µL into the striatum of adult NSG immunocompromised
mice (aged 4–8 wk). Coordinates were 1 mm anterior and 2 mm
lateral to the Bregma and 2.5 mm deep.
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